SpringerLink
Log in

Selective serotonin reuptake inhibitor use and the risk of hepatocellular carcinoma

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bhagavathula AS, Woolf B, Rahmani J, Vidyasagar K, Tesfaye W (2022) Selective serotonin reuptake inhibitor use and the risk of hepatocellular carcinoma: a systematic review and dose-response analysis of cohort studies with one million participants. Eur J Clin Pharmacol (Online ahead of print)

  2. Targownik LE, Suissa S (2015) Understanding and avoiding immortal-time bias in gastrointestinal observational research. Am J Gastroenterol 110(12):1647–1650

    Article  Google Scholar 

  3. Rawla P, Sunkara T, Muralidharan P, Raj JP (2018) Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn) 22(3):141–150

    CAS  Google Scholar 

  4. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC (2012) Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 107(1):46–52

    Article  CAS  Google Scholar 

  5. Chen DS (2007) Hepatocellular carcinoma in Taiwan. Hepatol Res 37(2):S101-105

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Public Health, College of Public Health and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan

    Shih-Wei Lai

  2. Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan

    Shih-Wei Lai & Chiu-Shong Liu

  3. Department of Occupational Safety and Health, College of Public Health, China Medical University, Taichung, Taiwan

    Bing-Fang Hwang

  4. School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan

    Chiu-Shong Liu

  5. College of Medicine, Tzu Chi University, Hualien, Taiwan

    Kuan-Fu Liao

  6. Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Tanzi District, No.66, Sec. 1, Fongsing Road, Taichung, 427, Taiwan

    Kuan-Fu Liao

Authors
  1. Shih-Wei Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bing-Fang Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiu-Shong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kuan-Fu Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kuan-Fu Liao.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lai, SW., Hwang, BF., Liu, CS. et al. Selective serotonin reuptake inhibitor use and the risk of hepatocellular carcinoma. Eur J Clin Pharmacol 78, 1197–1198 (2022). https://doi.org/10.1007/s00228-022-03306-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-022-03306-1

Search

Navigation